Glycoprotein non-metastatic b (GPNMB) has recently been identified as a gene that is over-expressed in numerous cancers, including TNBC, and often correlates with the metastatic phenotype. In breast cancer, GPNMB expression in the tumor epithelium is associated with a reduction in disease-free and overall survival. Based on these findings, glembatumumab vedotin (CDX-011), an antibody-drug conjugate that selectively targets GPNMB, is currently being investigated in clinical trials for patients with metastatic breast cancer and unresectable melanoma. This review discusses the physiological and potential pathological roles of GPNMB in normal and cancer tissues, respectively, and details the clinical advances and challenges in targeting GPNMB-expressing malignancies.
SELL IN MAY and GO AWAY!
$3 than and $1.72 now.....YOU SAY----I know nothing--- alright just like Schultz of Hogans Heroes, right??--LOL!
I know when a stock is under a short attack...and apparently YOU do not?
There is much everyone on this BOARD could learn from me and soon I will unveil it!
In the meantime it is what it is......$1.72 low and still Falling....
Why not compare elephants to apples. This is a stock that sells for more than ten times per share what GALE is going for with a 52-week low of $4.46 and it has run to $20. Go ahead. Join the party with others by paying $20 for the same shares they bought at $4 to $5 dollars. Or buy GALE at $1.70s and smile when it's $20.
Sentiment: Strong Buy
Frank: the two treatments (NeuVax & the attack on GPNMB overexpression) are NOT mutually exclusive. The CLDX protocols are aimed at Primary treatment modality, whereas NeuVax is designed for use in the Adjuvant Treatment setting. In reality, there could even be a potential collaborative effort between the two treatments: Treat the cancer First with the CLDX science, followed in the Adjuvant setting with the T-Cell support offered by NeuVax. Again, my major point is that the two treatments are NOT mutually exclusive of one another. In direct response to your posting: the two treatments do not represent "competition" as much as they might offer a new synergism in the cancer-fighting efforts. Dan
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.
Maric G, Rose AA, Annis MG, Siegel PM.
Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada ; Department of Medicine, McGill University, Montréal, Québec, Canada.
...apparently CLDX owns the rights to GPNMB and perhaps the Markets are re looking at GALE and downgrading the valuation of GALE as the recent low price of 1.73 now breaks support..it may be a good time for some to reconsider HOLDING a stock that seems to be in a perpetual free fall!
Some now see support at 1.49 which would be 50% haircut from the recent Top....its not like this is not deja voux...it has happened before w/ GALE which seems to be at the mercy of weak shareholders!
If you can not afford this further DECLINE which is in place firmly w/ GALE I would suggest you take immediate action!
Clearly GALE was a shining example of SELL IN MAY AND GO AWAY to some 4M!
05/01/2013 3 3 2.65 2.81 4,161,647
were U smart enough to recognize it than?
If not are you smart enough now NOT to REPEAT?